Associations of Prostate Cancer Risk Variants with Disease Aggressiveness: Results of the NCI-SPORE Genetics Working Group Analysis of 18,343 Cases

Brian T. Helfand,
Department of Surgery, Division of Urology, NorthShore University Health System, John and Carol Walter Center for Urological Health, Evanston, Illinois

Kimberly A. Roehl,
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Phillip R. Cooper,
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Barry McGuire,
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Liesel M. Fitzgerald,
Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria 3004, Australia

Geraldine Cancel-Tassin,
CeRePP ICPCG Group, Hopital Tenon, Assistance Publique-Hopitaux de Paris, 75020 Paris, France

Jean-Nicolas Cornu,
CeRePP ICPCG Group, Hopital Tenon, Assistance Publique-Hopitaux de Paris, 75020 Paris, France

Scott Bauer,
Genome Analysis Core Facility, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California

Erin L. Van Blarigan,
Genome Analysis Core Facility, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California

Xin Chen,
Department of Pathology and Laboratory Medicine, University of California, Irvine

David Duggan,
Integrated Cancer Genomics Division, TGen, Phoenix, Arizona

Elaine A. Ostrander,
FHCRC/NHGRI ICPCG Group, Seattle, Washington

Corresponding Author: William J. Catalona, MD (WCatalona@nmff.org, Phone 312-695-4471, FAX 312-695-1536).

Mary Gwo-Shu,

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Zuo-Feng Zhang,

Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California

Shen-Chih Chang,

Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California

Somee Jeong,

Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California

Sonja Berndt,

Division of Cancer Epidemiology & Genetics, Occupational and Environmental Epidemiology Branch, National Cancer Institute, Bethesda, Maryland

Shannon K. McDonnell,

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota

Rick Kittles,

Department of Surgery, Division of Urology, University of Arizona, Tucson, Arizona

Benjamin A. Rybicki,

Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan

Matthew Freedman,

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Phil Kantoff,

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Mark Pomerantz,

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

Joan P. Breyer,

Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee

Jeffrey R. Smith,

Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee

Timothy R. Rebbeck,

Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Dan Mercola,

Department of Pathology and Laboratory Medicine, University of California, Irvine, California

William B Isaacs,
Department of Urology, Johns Hopkins University, Baltimore, Maryland

Fredrick Wiklund,
University of Umeå ICPCG Group, Umeå, Sweden

Olivier Cussenot,
CeRePP ICPCG Group, Hopital Tenon, Assistance Publique-Hopitaux de Paris, 75020 Paris,
France

Stephen N. Thibodeau,
Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

Daniel J. Schaid,
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota

Lisa Cannon-Albright,
Division of Genetic Epidemiology, Department of Medicine, University of Utah School of
Medicine, Salt Lake City, Utah

Kathy A. Cooney,
Department of Urology, Department of Internal Medicine, University of Michigan Medical School,
Ann Arbor, Michigan

Stephen J. Chanock,
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland

Janet L. Stanford,
FHCRC/NHGRI ICPCG Group, Seattle, Washington

June M. Chan,
Genome Analysis Core Facility, Helen Diller Family Comprehensive Cancer Center, University of
California, San Francisco, California

John Witte,
Genome Analysis Core Facility, Helen Diller Family Comprehensive Cancer Center, University of
California, San Francisco, California

Jianfeng Xu,
Program for Personalized Cancer Care and Department of Surgery, NorthShore University
HealthSystem, Evanston, Illinois

Jeanette T. Bensen,
Department of Epidemiology, Gillings School of Global Public Health, and the Lineberger
Comprehensive Cancer Center University of North Carolina at Chapel Hill, North Carolina

Jack A. Taylor, and
Epidemiology Branch and Laboratory of Molecular Carcinogenesis, National Institute of
Environmental Health Sciences, Research Triangle Park, North Carolina

William J. Catalona
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Keywords

Prostate cancer; aggressiveness; SNP; screening; Europeans; African-Americans

Introduction

Current serum prostate-specific antigen (PSA)-based screening practices cannot reliably distinguish between men with indolent disease versus those with life-threatening disease. In this regard, PSA-based screening has been associated with an "over-diagnosis" of prostate cancer (PC), with some men possibly being diagnosed and treated for a seemingly indolent tumor that may never have been detected nor caused symptoms (Andriole et al. 2009; Schroder et al. 2009). Accordingly, there is an urgent need for new biomarkers that can better differentiate tumor behavior and clinical outcome.

Genome-wide association studies (GWAS) of PC patients and controls have identified approximately 100 different single nucleotide polymorphisms (SNPs) associated with the overall risk of being diagnosed with PC (Al Olama et al. 2014; Amundadottir et al. 2006; Choudhury et al. 2012; Eeles et al. 2008b; Eeles et al. 2013; Gudmundsson et al. 2009; Gudmundsson et al. 2007a; Gudmundsson et al. 2008; Gudmundsson et al. 2007b; Haiman et al. 2007; Thomas et al. 2008; Yeager et al. 2007). Most of these initial discovery studies have compared men with non-aggressive or moderately-aggressive tumors to controls without known PC. Although some of these studies have been performed or validated in different racial populations (Cook et al. 2014; Freedman et al. 2006; Haiman et al. 2011; Han et al. 2014; Wang et al. 2012; Zheng et al. 2010), the great majority have been limited to men of European ancestry (Ishak and Giri 2011). Thus, while the results advance the knowledge of genetic factors associated with PC risk, in general, they have not been focused on clinically-significant disease nor directed towards ethnic groups at greatest risk of dying of PC, such as men of African ancestry.

Some of the initial discovery GWAS attempted to evaluate the associations between specific PC-risk SNPs and various aspects of disease aggressiveness (e.g., Gleason score). However, these studies were generally performed as post hoc analyses and involved heterogeneous definitions of disease aggressiveness. In addition, most of these analyses compared the frequency of genetic variants in men with high-grade disease to controls and men with low-grade disease to controls. Only a relatively small proportion of GWAS in PC have been designed to evaluate the associations between genetic variants and clinically significant outcomes (e.g., disease aggressiveness) as their primary outcome measure. Xu et al. (2010) reported that the minor allele of single nucleotide polymorphism (SNP), rs4054823 on chromosome 17p12 was present at a significantly greater frequency in men with Gleason score 8 tumors and higher-stage disease (pT3b). Lin et al (2011) used a candidate gene approach to identify a panel of 5 SNPs associated with PC-specific mortality. However, other studies have not found robust associations with PC-specific mortality (Penney et al. 2010). Other research groups have reported associations between individual SNPs on chromosomes 3p12, 8q24, 10q11, and 15q13 and the pathology features characteristic of aggressive PC (Ahn et al. 2011; Bensen et al. 2013; FitzGerald et al. 2011). A meta-analysis

aimed at determining whether genetic variants were associated with adverse pathology features reported that SNP rs11672691 showed associations with more aggressive tumors (Amin Al Olama et al. 2013). Additionally, results from other GWAS and linkage analyses have reported risk loci associated with aggressive disease amongst familial cases (Casey et al. 2006; Chang et al. 2005; Gudmundsson et al. 2008; Kirkland et al. 2010; Liu et al. 2011; Nam et al. 2011; Nurminen et al. 2011; Schaid et al. 2006; Schaid et al. 2007; Slager et al. 2006; Stanford et al. 2006; Witte et al. 2000). In addition, Shui et al. reported that 8 SNPs were associated with lethal PC (Shui et al. 2014). The results of these studies are limited by the relatively small cohorts of PC patients of European ancestry studied, the heterogeneous definitions of aggressive disease used, reliance upon clinical (versus surgical) grading and staging of tumors, and lack of validation in diverse racial populations. Validation is essential to provide generalizability of results, especially since most of the genetic variants have only modest effects on disease risk and aggressiveness (OR 1.1–1.3).

The National Cancer Institute Prostate Cancer Genetics Working Group (GWG) was assembled to conduct a case-case association study of aggressive and non-aggressive PC (Catalona et al. 2011) using a panel of the then 36 validated SNPs associated with PC risk. In order to eliminate some of the variability in definitions of disease aggressiveness, only PC cases with complete information on disease aggressiveness and clinical follow-up were included in the analyses. Herein, we report our findings from a retrospective evaluation of more than 18,000 men with PC, including >8,000 men with aggressive disease, 5,000 men with non-aggressive disease, and >1800 African American men.

Methods and Materials

Study Samples

Nineteen PC research groups participated in this study and contributed clinical and genotype data (Supplemental Table 1). All institutions provided de-identified genotype and clinical information regarding pathologic tumor staging and grading to a central Data Coordinating Center (Northwestern University). The genotypes of 36 SNPs previously validated to be associated with PC risk were collected on a total of 25,674 cases with PC, including 23,278 men of self-reported European ancestry, 2,129 of African ancestry, and 267 of unknown ancestry. This panel of SNPs was chosen for evaluation because at the time of the 2010 NCI-SPORE GWG conference, it included the most comprehensive list of validated PC-risk SNPs. While information was collected on all 36 SNPs, there were varying numbers of SNPs available for analysis from each site (Supplemental Table 1). Details on the methodologies for genotyping at each individual institution are presented in Supplemental Table 2.

For men treated with surgery for PC, the pathology tumor grade and stage were used in the analysis. For men who underwent non-surgical treatments, the clinical stage and biopsy Gleason score were used. In addition, biochemical (PSA) evidence of tumor recurrence status and PC-specific mortality was documented for both cohorts of men. For the purposes of the present study, disease aggressiveness was defined in two ways: First, "aggressive disease" was indicated by PC-specific death, or distant metastasis, or lymph node involvement, or seminal vesicle invasion, or extracapsular tumor extension or Gleason score

8. "Non-aggressive" disease was defined strictly as Gleason 6 and clinically localized and organ-confined disease. For men who underwent radiation therapy, their clinical stage and grade was used to define organ-confined disease. "Intermediate disease" was defined as non-lethal with either Gleason 7 disease or biochemical recurrence. All cohorts required documentation of at least 3 years follow-up from the time of diagnosis and/or treatment, no high-risk pathology features, metastases or PC-specific mortality. A second overlapping definition of "aggressive disease" was based solely on the Gleason grade of the tumor. For this analysis, high-, intermediate- and low-grade tumors were defined by Gleason scores 8, 7, and 6, respectively. Because there was incomplete data on the primary and secondary Gleason patterns, analyses that separated Gleason scores 3+4 and 4+3 could not be performed.

Exclusion Criteria

Men were excluded from the analysis if they did not have documentation of pathology Gleason score for men undergoing prostatectomy (n = 48, 0.2%), clinical Gleason score for men undergoing radiation therapy (147, 0.6%), data on PSA (n = 1481, 5.8%), staging (n = 3408, 13.3%), and/or clinical follow-up information (n = 4878, 19.0%). Men were also excluded if they did not have documentation of either European or African-American ancestry (n = 267, 1.0%).

Statistical Analyses

Sensitivity analyses were performed comparing the genotypes of men fulfilling and those not meeting inclusion criteria. With the exception of one SNP, there were no differences between the included and excluded groups. However, the allele counts of SNP rs16902094 on chromosome 8q24 were significantly different between excluded and included groups of men of European ancestry. This difference was eliminated after adjusting for length of clinical follow-up, i.e., when outcomes were compared among patients who had similar follow-up intervals.

Analyses were performed for the entire cohort and separately by self-reported race (European and African-American). The reference allele used for all analyses was defined by the allele previously associated with PC risk. We used logistic regression analysis to test for the association between the allele counts for each individual SNP and the presence of PC within the included cohorts. Alleles were coded in a log-additive manner, whereby the counts reflected the number of previously associated alleles. For some analyses, we stratified cases into those with aggressive, intermediate, or non-aggressive disease, and we treated these case groups as ordinal outcomes. The institutional site was documented to adjust for possible differences in genotyping methodology. As such, institutional site was included in the logistic regression model as a covariate using Northwestern University and the referent site

Multinomial logistic regression analysis was used to examine the association between allele counts (again for the previously-reported PC risk allele) and tumor aggressiveness as well as the potential association between allele counts and Gleason score. The Bonferroni correction was used to adjust for multiple testing.

Results

A total of 18,343 men (16,515 of European ancestry and 1,828 of African ancestry) met inclusion criteria. The clinical and pathology features of these men are shown (Table 1). Of the Caucasian men, 49.8%, 21.6% and 28.6% had aggressive, intermediate and non-aggressive disease, respectively. Similarly, 39.4%, 34.2% and 26.4% men of African heritage were categorized as having aggressive, intermediate or non-aggressive disease. The numbers of men genotyped for each of the 36 SNPs are shown in Table 1 and Supplemental Table 3.

After adjusting for multiple testing, case-case logistic analyses comparing the genotypes of the entire cohort with aggressive, intermediate and non-aggressive disease showed that only the minor allele of rs2735839 (G) on chromosome 19q13 remained significantly (and inversely) associated with aggressive disease ($p = 9.343 \times 10^{-8}$; Table 2). Similarly, after correction for multiple testing, only the same SNP was significantly (and inversely) associated with the presence of aggressive disease in the European ($p = 1.042 \times 10^{-5}$) and African-American ($p = 2.0 \times 10^{-4}$; Table 2) cohorts

We also compared the allele count frequencies in men of European ancestry with high (Gleason score 8), intermediate (Gleason score =7), and low-grade disease (Gleason score =6). After correction for multiple testing, only the minor allele (G) of rs2735839 on 19q13 remained significantly (and inversely) associated with high-grade disease in the entire cohort ($p=1.389 \times 10^{-8}$). Again, after correction for multiple testing, only the same SNP retained its significance within European ($p=1.862 \times 10^{-5}$) and African-American men ($p=4.667 \times 10^{-4}$; Table 3).

To determine whether the association between rs2735839 and high-risk and high-grade disease was due to a PSA screening bias, we performed subset analyses using various PSA cutoffs (Table 4). There was a significant and inverse association between rs2735839 and aggressive disease at nearly every PSA cutoff in both cohorts of European and African-American men.

Discussion

Most previous studies of PC-risk alleles were not designed to identify genetic variants associated with aggressive disease because they were largely focused on men with a diagnosis of PC, irrespective of disease aggressiveness. In contrast, our study was aimed at identifying variants that are associated with PC aggressiveness rather than overall risk of PC (Helfand et al. 2010).

Previous studies have identified associations between SNPs within or near the PSA gene (*KLK3*) and high-grade tumors and adverse clinical outcomes (Bensen et al. 2013; Cramer et al. 2008; Gudmundsson et al. 2010; Lindstrom et al. 2011; Reinhardt et al. 2013; Slager et al. 2003; Xu et al. 2008). For example, using cohorts of European and Ashkenazi Jewish ancestry, two studies found that SNP rs2735839 in *KLK3* was associated with PC-specific mortality (Gallagher et al. 2010; Pomerantz et al. 2011). In addition, the SNP rs2735839 on chromosome 19q13 within the *KLK3* (PSA) gene has been previously evaluated in men of

European ancestry for its association with clinico-pathologic features of prostate tumors (Bensen et al. 2013; He et al. 2014; Kader et al. 2009; Lindstrom et al. 2011; Nobata et al. 2012; Pomerantz et al. 2011; Xu et al. 2008). Taken together, the G allele has been associated with PC risk and increased serum PSA levels, but also with significantly lower disease aggressiveness (Bensen et al. 2013). However, results have been inconsistent. In the present study of large cohorts of both European and African-American men, this SNP was present at significantly different frequencies amongst men with aggressive and high-grade disease compared to those with non-aggressive or low-grade disease. Since this genetic variant lies within the *KLK3* gene, it is not surprising that variants within or around this gene could influence PC aggressiveness (Gudmundsson et al. 2010; Gudmundsson et al. 2009; He et al. 2014; Hsu et al. 2009; Kader et al. 2009; Lange et al. 2012; Pal et al. 2007; Penney et al. 2011; Schaid et al. 2007; Xu et al. 2008). Although the mechanism(s) of this association are unclear, it is possible that it may reflect, at least in part, a PSA detection bias (e.g., G allele of rs2735839 is associated with lower PSA expression and a delay in PC diagnosis). However, a PSA detection bias may not be sufficient to explain all of the current findings. For example, data from non-PSA-screened cohorts (Eeles et al. 2008a) and from men with low PSA values (Table 4) and functional studies (Lai et al. 2007) support the possibility of other potential roles for this locus, including PSA production, and the intrinsic risk of PC overall and of aggressive disease. Regardless, this SNP appears to have the potential ability to discriminate between aggressive and non-aggressive disease. Specifically, in men of European ancestry, this SNP discriminated between aggressive and non-aggressive disease within men with relatively low PSA values < 4ng/mL (Table 4). Because the clinical and pathology features were used to define the groups, we were not able to determine whether this allele adds independent prognostic information. Therefore, additional studies aimed at fully evaluating its clinical utility are needed.

Our results reveal similar findings with SNP rs2735839, whether we defined aggressive disease as high-grade disease (Gleason score 8) alone or a more comprehensive definition (PC-specific death, distant metastasis, lymph node involvement, seminal vesicle invasion, extracapsular tumor extension) (Tables 2 and 3). Taken together, our results suggest that Gleason score may be the driving force for determining the genetic basis of aggressive disease. While the mechanisms largely underlying their association with aggressive disease has largely remains elusive, it appears that PC-risk SNPs may influence gene expression including PSA(Chen et al. 2015; Jin et al. 2013).

It is well established that men of African descent are at significantly increased risk of PC, with a greater proportion being diagnosed at an earlier age with aggressive disease (Moul 2000; Zeliadt et al. 2003). Specifically, African- American men have a 50% higher incidence and more than a 240% higher mortality rate of PC than Caucasian men (Hsing and Chokkalingam 2006) (Taksler et al. 2012). Unfortunately, the majority of genetic studies have not included large cohorts of African-American men. The present study is strengthened by the fact that it highlights both similarities and differences between African-American and European men. For example, there were many more SNPs that were marginally associated with high-risk and high–grade disease in the European compared to African-American men (Tables 2 and 3). As stated above, this is likely related to the mechanisms of their initial

discovery in Caucasian cohorts (Han et al. 2014). Other nearby or related SNPs may also be associated with aggressive disease in African-Americans, and more studies within this population are needed. Interestingly, both racial populations showed an association between the aggressive phenotype and the minor allele of rs2735839 (G). This suggests a robustness of the association in other racial populations as well as a common genetic mechanism for PC aggressiveness.

Our study has several strengths, including its involvement of large cohorts with aggressive prostate tumors. This allowed the identification of PC-risk SNPs with at least marginally significant associations with aggressive disease. These small relative risks of aggressive disease are somewhat expected given similar associations between these SNPs and overall disease risk. However, based upon the fact that these SNPs are common within the general population and have a low penetrance, we cannot exclude the possibility of false positive results. Additionally, we used a widely validated subset of PC risk variants in the present study. This relatively limited subset of 36 SNPs allowed us to evaluate more fully the SNPs in a new context without having the same statistical constraints as many GWAS studies that involve millions of other SNPs. However, this same subset also limited the scope of our results, as it did not permit the identification of other more recently validated risk SNPs or novel genetic variations that may better predict PC aggressiveness. Furthermore, we did not have genotype data on all 36 SNPs in all patients included in the study. This limited the statistical power. Therefore, future case-case GWAS involving large cohorts of men with complete genotype data are needed. In addition, future complementary case-control studies evaluating these same SNPs would be needed to better define the direction and magnitude of the associations with aggressive disease. Additionally, although our study population represents one of the largest cohorts of men with African-American ancestry, the statistical power remains limited, and the results require replication in larger, independent datasets. Furthermore, it should be noted that there may have been a selection bias present since the proportion of African-American men with aggressive disease included in the cohort was significantly less than among European-Americans. Furthermore, our results may have been confounded by the fact that race was self-reported and lacked associated genetic information on ancestry. While our results are limited by the definition of disease aggressiveness used, it emphasizes the need for replication, as the majority of prior aggressiveness loci have failed to be replicated.

In summary, we provide further evidence that a single PC risk SNP (rs2735839) on chromosome 19q13 may be associated with high-risk and high-grade PC. Future prospective designed, case-case GWAS should be performed to identify additional SNPs associated with PC aggressiveness

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

Ahn J, Kibel AS, Park JY, Rebbeck TR, Rennert H, Stanford JL, Ostrander EA, Chanock S, Wang MH, Mittal RD, Isaacs WB, Platz EA, Hayes RB. Prostate cancer predisposition loci and risk of

metastatic disease and prostate cancer recurrence. Clin Cancer Res. 2011; 17:1075–81. 1078-0432.CCR-10-0881 [pii] . 10.1158/1078-0432.CCR-10-0881 [PubMed: 21343373]

Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Roder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokolorczyk D, Kluzniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 201410.1038/ng.3094

Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dork T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet. 2013; 22:408–15.10.1093/hmg/dds425 [PubMed: 23065704]

Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Balter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006; 38:652–8.10.1038/ng1808 [PubMed: 16682969]

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360:1310–9. NEJMoa0810696 [pii] . 10.1056/NEJMoa0810696 [PubMed: 19297565]

Bensen JT, Xu Z, Smith GJ, Mohler JL, Fontham ET, Taylor JA. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate. 2013; 73:11–22.10.1002/pros.22532 [PubMed: 22549899]

Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, Curran AP, McGreevy MR, Catalona WJ, Klein EA, Witte JS. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet. 2006; 15:735–41.10.1093/hmg/ddi487 [PubMed: 16434482]

Catalona WJ, Bailey-Wilson JE, Camp NJ, Chanock SJ, Cooney KA, Easton DF, Eeles RA, FitzGerald LM, Freedman ML, Gudmundsson J, Kittles RA, Margulies EH, McGuire BB,

Ostrander EA, Rebbeck TR, Stanford JL, Thibodeau SN, Witte JS, Isaacs WB. National Cancer Institute Prostate Cancer Genetics Workshop. Cancer Res. 2011; 71:3442–6.10.1158/0008-5472.can-11-0314 [PubMed: 21558387]

Chang BL, Isaacs SD, Wiley KE, Gillanders EM, Zheng SL, Meyers DA, Walsh PC, Trent JM, Xu J, Isaacs WB. Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate. 2005; 64:356–61.10.1002/pros.20249 [PubMed: 15754351]

Chen X, McClelland M, Jia Z, Rahmatpanah FB, Sawyers A, Trent JM, Duggan D, Mercola D. The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression in tumor-adjacent stroma. Oncotarget. 2015 In Press.

Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T. The role of genetic markers in the management of prostate cancer. Eur Urol. 2012; 62:577–87.10.1016/j.eururo.2012.05.054 [PubMed: 22695242]

Cook MB, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chung CC, Chokkalingam AP, Chu LW, Yeager M, Hutchinson A, Yu K, Rand KA, Haiman CA, Hoover RN, Hsing AW, Chanock SJ. African Ancestry Prostate Cancer GC. A genome-wide association study of prostate cancer in West African men. Hum Genet. 2014; 133:509–21.10.1007/s00439-013-1387-z [PubMed: 24185611]

Cramer SD, Sun J, Zheng SL, Xu J, Peehl DM. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17:2451–7. 17/9/2451 [pii] . 10.1158/1055-9965.EPI-08-0374 [PubMed: 18768516]

Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Collaborators UKGPCS, British Association of Urological Surgeons' Section of O Collaborators UKPS. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008a; 40:316–21.10.1038/ng.90 [PubMed: 18264097]

Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008b; 40:316–21. ng.90 [pii]. 10.1038/ng.90 [PubMed: 18264097]

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013; 45:385–91. 391e1-2.10.1038/ng.2560 [PubMed: 23535732]

FitzGerald LM, Kwon EM, Conomos MP, Kolb S, Holt SK, Levine D, Feng Z, Ostrander EA, Stanford JL. Genome-wide association study identifies a genetic variant associated with risk for

more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20:1196–203. 1055-9965.EPI-10-1299 [pii]. 10.1158/1055-9965.EPI-10-1299 [PubMed: 21467234]

Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Altshuler D, Henderson BE, Reich D. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006; 103:14068–73.10.1073/pnas. 0605832103 [PubMed: 16945910]

Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Hallden C, Dutra-Clarke A, Klein RJ, Scardino PT, Eastham JA, Lilja H, Kirchhoff T, Offit K. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res. 2010; 16:2819–32.10.1158/1078-0432.CCR-10-0028 [PubMed: 20460480]

Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, Gudjonsson SA, Stacey SN, Gylfason A, Sigurdsson A, Holm H, Bjornsdottir US, Eyjolfsson GI, Navarrete S, Fuertes F, Garcia-Prats MD, Polo E, Checherita IA, Jinga M, Badea P, Aben KK, Schalken JA, van Oort IM, Sweep FC, Helfand BT, Davis M, Donovan JL, Hamdy FC, Kristjansson K, Gulcher JR, Masson G, Kong A, Catalona WJ, Mayordomo JI, Geirsson G, Einarsson GV, Barkardottir RB, Jonsson E, Jinga V, Mates D, Kiemeney LA, Neal DE, Thorsteinsdottir U, Rafnar T, Stefansson K. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med. 2010; 2:62ra92. 2/62/62ra92 [pii]. 10.1126/scitranslmed.3001513

Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, Benediktsdottir KR, Magnusdottir DN, Orlygsdottir G, Jakobsdottir M, Stacey SN, Sigurdsson A, Wahlfors T, Tammela T, Breyer JP, McReynolds KM, Bradley KM, Saez B, Godino J, Navarrete S, Fuertes F, Murillo L, Polo E, Aben KK, van Oort IM, Suarez BK, Helfand BT, Kan D, Zanon C, Frigge ML, Kristjansson K, Gulcher JR, Einarsson GV, Jonsson E, Catalona WJ, Mayordomo JI, Kiemeney LA, Smith JR, Schleutker J, Barkardottir RB, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009; 41:1122–6.10.1038/ng.448 [PubMed: 19767754]

Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007a; 39:631–7.10.1038/ng1999 [PubMed: 17401366]

Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Blondal T, Jakobsdottir M, Stacey SN, Kostic J, Kristinsson KT, Birgisdottir B, Ghosh S, Magnusdottir DN, Thorlacius S, Thorleifsson G, Zheng SL, Sun J, Chang BL, Elmore JB, Breyer JP, McReynolds KM, Bradley KM, Yaspan BL, Wiklund F, Stattin P, Lindstrom S, Adami HO, McDonnell SK, Schaid DJ, Cunningham JM, Wang L, Cerhan JR, St Sauver JL, Isaacs SD, Wiley KE, Partin AW, Walsh PC, Polo S, Ruiz-Echarri M, Navarrete S, Fuertes F, Saez B, Godino J, Weijerman PC, Swinkels DW, Aben KK, Witjes JA, Suarez BK, Helfand BT, Frigge ML, Kristjansson K, Ober C, Jonsson E, Einarsson GV, Xu J, Gronberg H, Smith JR, Thibodeau SN, Isaacs WB, Catalona WJ, Mayordomo JI, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008; 40:281–3.10.1038/ng.89 [PubMed: 18264098]

Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So WY, Tong PC, Ng MC, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, van

Vierssen Trip O, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CN, Rotimi C, Chan JC, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007b; 39:977–83.10.1038/ng2062 [PubMed: 17603485]

Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, Diver WR, Witte JS, Hsing AW, Nemesure B, Rebbeck TR, Cooney KA, Xu J, Kibel AS, Hu JJ, John EM, Gueye SM, Watya S, Signorello LB, Hayes RB, Wang Z, Yeboah E, Tettey Y, Cai Q, Kolb S, Ostrander EA, Zeigler-Johnson C, Yamamura Y, Neslund-Dudas C, Haslag-Minoff J, Wu W, Thomas V, Allen GO, Murphy A, Chang BL, Zheng SL, Leske MC, Wu SY, Ray AM, Hennis AJ, Thun MJ, Carpten J, Casey G, Carter EN, Duarte ER, Xia LY, Sheng X, Wan P, Pooler LC, Cheng I, Monroe KR, Schumacher F, Le Marchand L, Kolonel LN, Chanock SJ, Van Den Berg D, Stram DO, Henderson BE. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011; 43:570–3.10.1038/ng.839 [PubMed: 21602798]

Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet. 2007; 39:638–44. ng2015 [pii]. 10.1038/ng2015 [PubMed: 17401364]

Han Y, Signorello LB, Strom SS, Kittles RA, Rybicki BA, Stanford JL, Goodman PJ, Berndt SI, Carpten J, Casey G, Chu L, Conti DV, Rand KA, Diver WR, Hennis AJ, John EM, Kibel AS, Klein EA, Kolb S, Marchand LL, Leske MC, Murphy AB, Neslund-Dudas C, Park JY, Pettaway C, Rebbeck TR, Gapstur SM, Zheng SL, Wu SY, Witte JS, Xu J, Isaacs W, Ingles SA, Hsing A, The PC, The EG-ONC, Easton DF, Eeles RA, Schumacher FR, Chanock S, Nemesure B, Blot WJ, Stram DO, Henderson BE, Haiman CA. Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer. 201410.1002/ijc.29066

He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X. The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients. Clin Cancer Res. 2014; 20:5133–9.10.1158/1078-0432.CCR-14-0661 [PubMed: 25274378]

Helfand BT, Loeb S, Kan D, Catalona WJ. Number of prostate cancer risk alleles may identify possibly 'insignificant' disease. BJU Int. 2010; 106:1602–6. BJU9440 [pii]. 10.1111/j.1464-410X. 2010.09440.x [PubMed: 20590552]

Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006; 11:1388–413. 1891 [pii]. [PubMed: 16368524]

Hsu FC, Sun J, Wiklund F, Isaacs SD, Wiley KE, Purcell LD, Gao Z, Stattin P, Zhu Y, Kim ST, Zhang Z, Liu W, Chang BL, Walsh PC, Duggan D, Carpten JD, Isaacs WB, Gronberg H, Xu J, Zheng SL. A novel prostate cancer susceptibility locus at 19q13. Cancer Res. 2009; 69:2720–3.10.1158/0008-5472.CAN-08-3347 [PubMed: 19318570]

Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev. 2011; 20:1599–610. 1055-9965.EPI-11-0312 [pii] . 10.1158/1055-9965.EPI-11-0312 [PubMed: 21715604]

Jin G, Zheng SL, Lilja H, Kim ST, Tao S, Gao Z, Young T, Wiklund F, Feng J, Isaacs WB, Rittmaster RS, Gronberg H, Condreay LD, Sun J, Xu J. Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. Neoplasia. 2013; 15:95–101. [PubMed: 23359319]

Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Isaacs W. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate. 2009; 69:1195–205.10.1002/pros.20970 [PubMed: 19434657]

Kirkland CT, Price DK, Figg WD. Genetic variant associated with aggressive not indolent prostate cancer. Cancer Biol Ther. 2010; 9:957–8. [PubMed: 20581469]

Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, Spurdle AB, Morris CP, Harris J, Clements JA. PSA/ KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis. 2007; 28:1032–9.10.1093/carcin/bgl236 [PubMed: 17151093]

Lange EM, Salinas CA, Zuhlke KA, Ray AM, Wang Y, Lu Y, Ho LA, Luo J, Cooney KA. Early onset prostate cancer has a significant genetic component. Prostate. 2012; 72:147–56.10.1002/pros. 21414 [PubMed: 21538423]

Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Gronberg H, Stanford JL. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011; 20:1928–36.10.1158/1055-9965.epi-11-0236 [PubMed: 21846818]

Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, Diver WR, Severi G, Allen N, Andriole G, Bueno-de-Mesquita B, Chanock SJ, Crawford D, Gaziano JM, Giles GG, Giovannucci E, Guo C, Haiman CA, Hayes RB, Halkjaer J, Hunter DJ, Johansson M, Kaaks R, Kolonel LN, Navarro C, Riboli E, Sacerdote C, Stampfer M, Stram DO, Thun MJ, Trichopoulos D, Virtamo J, Weinstein SJ, Yeager M, Henderson B, Ma J, Le Marchand L, Albanes D, Kraft P. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3. PLoS One. 2011; 6:e17142.10.1371/journal.pone. 0017142 [PubMed: 21390317]

Liu X, Cheng I, Plummer SJ, Suarez BK, Casey G, Catalona WJ, Witte JS. Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. Prostate. 2011; 71:682–9.10.1002/pros.21284 [PubMed: 20945404]

Moul JW. Screening for prostate cancer in African Americans. Curr Urol Rep. 2000; 1:57–64. [PubMed: 12084342]

Nam RK, Zhang W, Siminovitch K, Shlien A, Kattan MW, Klotz LH, Trachtenberg J, Lu Y, Zhang J, Yu C, Toi A, Loblaw DA, Venkateswaran V, Stanimirovic A, Sugar L, Malkin D, Seth A, Narod SA. New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther. 2011; 12:997–1004.10.4161/cbt.12.11.18366 [PubMed: 22130093]

Nobata S, Hishida A, Naito M, Asai Y, Mori A, Kuwabara M, Katase S, Okada R, Morita E, Kawai S, Hamajima N, Wakai K. Association between KLK3 rs2735839 G/A polymorphism and serum PSA levels in Japanese men. Urol Int. 2012; 89:39–44.10.1159/000332197 [PubMed: 22433834]

Nurminen R, Wahlfors T, Tammela TL, Schleutker J. Identification of an aggressive prostate cancer predisposing variant at 11q13. Int J Cancer. 2011; 129:599–606.10.1002/ijc.25754 [PubMed: 21064104]

Pal P, Xi H, Sun G, Kaushal R, Meeks JJ, Thaxton CS, Guha S, Jin CH, Suarez BK, Catalona WJ, Deka R. Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum Genet. 2007; 122:251–9.10.1007/ s00439-007-0394-3 [PubMed: 17593395]

Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010; 19:2869–76.10.1158/1055-9965.EPI-10-0601 [PubMed: 20978177]

Penney KL, Schumacher FR, Kraft P, Mucci LA, Sesso HD, Ma J, Niu Y, Cheong JK, Hunter DJ, Stampfer MJ, Hsu SI. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011; 32:853–9. bgr050 [pii] . 10.1093/carcin/bgr050 [PubMed: 21421545]

Pomerantz MM, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011; 4:719–28.10.1158/1940-6207.CAPR-10-0292 [PubMed: 21367958]

Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, Loeb S. Prostate Cancer Risk Alleles are Associated with Prostate Cancer Volume and Prostate Size. J Urol. 201310.1016/j.juro. 2013.12.030

Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh CL, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TL, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Catalona WJ, Suarez BK, Roehl KA. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet. 2006; 120:471–85.10.1007/s00439-006-0219-9 [PubMed: 16932970]

Schaid DJ, Stanford JL, McDonnell SK, Suuriniemi M, McIntosh L, Karyadi DM, Carlson EE, Deutsch K, Janer M, Hood L, Ostrander EA. Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum Genet. 2007; 121:729–35.10.1007/ s00439-007-0368-5 [PubMed: 17486369]

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360:1320–8. NEJMoa0810084 [pii] . 10.1056/NEJMoa0810084 [PubMed: 19297566]

Shui IM, Lindstrom S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Le Marchand L, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014; 65:1069–75.10.1016/j.eururo.2013.12.058 [PubMed: 24411283]

Slager SL, Schaid DJ, Cunningham JM, McDonnell SK, Marks AF, Peterson BJ, Hebbring SJ, Anderson S, French AJ, Thibodeau SN. Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet. 2003; 72:759–62.10.1086/368230 [PubMed: 12563560]

Slager SL, Zarfas KE, Brown WM, Lange EM, McDonnell SK, Wojno KJ, Cooney KA. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate. 2006; 66:173–9.10.1002/pros.20332 [PubMed: 16173044]

Stanford JL, McDonnell SK, Friedrichsen DM, Carlson EE, Kolb S, Deutsch K, Janer M, Hood L, Ostrander EA, Schaid DJ. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate. 2006; 66:317–25.10.1002/pros.20349 [PubMed: 16245279]

Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012; 118:4280–9.10.1002/cncr.27379 [PubMed: 22246942]

Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008; 40:310–5.10.1038/ng.91 [PubMed: 18264096]

Wang M, Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, Wang Z, Chen H, Gao X, Wang G, Chu LW, Ding Q, OuYang J, Huang Y, Chen Y, Gao YT, Zhang ZF, Rao J, Shi R, Wu Q, Zhang Y, Jiang H, Zheng J, Hu Y, Guo L, Lin X, Tao S, Jin G, Sun J, Lu D, Zheng SL, Sun Y, Mo Z, Yin C, Zhang Z, Xu J. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case-control study in the ChinaPCa consortium. Carcinogenesis. 2012; 33:356–60. bgr279 [pii] . 10.1093/carcin/bgr279 [PubMed: 22114074]

Witte JS, Goddard KA, Conti DV, Elston RC, Lin J, Suarez BK, Broman KW, Burmester JK, Weber JL, Catalona WJ. Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet. 2000; 67:92–9. S0002-9297(07)62435-5 [pii] . 10.1086/302960 [PubMed: 10825281]

Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu Y, Hsu FC, Wiklund F, Turner AR, Adams TS, Liu W, Trock BJ, Partin AW, Chang B, Walsh PC, Gronberg H, Isaacs W, Zheng S. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res. 2008; 14:5819–24.10.1158/1078-0432.CCR-08-0934 [PubMed: 18794092]

Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, Kader AK, Li G, Purcell LD, Kim ST, Hsu FC, Stattin P, Hugosson J, Adolfsson J, Walsh PC, Trent JM, Duggan D, Carpten J, Gronberg H, Isaacs WB. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A. 2010; 107:2136–40.10.1073/pnas.0914061107 [PubMed: 20080650]

Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007; 39:645–9. ng2022 [pii] . 10.1038/ng2022 [PubMed: 17401363]

Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer. 2003; 98:496–503.10.1002/cncr.11492 [PubMed: 12879465]

Zheng SL, Hsing AW, Sun J, Chu LW, Yu K, Li G, Gao Z, Kim ST, Isaacs WB, Shen MC, Gao YT, Hoover RN, Xu J. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate. 2010; 70:425–32.10.1002/pros.21076 [PubMed: 19866473]

Table 1

Demographic and Clinico-pathologic Information

	Overall		Non-Aggressive		Intermediate Aggressive		Aggressive	
	N	%	N	%	N	%	N	%
N	18343	100	5213	28.4	4188	22.8	8942	48.8
Median Age at Diagnosis	61	34–93	60	34–84	60	35–79.7	63	36–93
Mean Age at Diagnosis	61.3	8.1	59.8	7.7	59.9	7.6	62.9	8.2
<55	3636	19.8	1260	24.2	1025	24.5	1351	15.1
55–64	8183	44.6	2563	49.2	2007	47.9	3613	40.4
GW65–74	5054	27.6	1246	23.9	1037	24.8	2771	31
>74	969	5.3	144	2.8	119	2.8	706	7.9
Unknown	501	2.7	0	0	0	0	501	5.6
Race								
European ancestry	16515	90	4731	90.8	3563	85.1	8221	91.9
African-American ancestry	1828	10	482	9.2	625	14.9	721	8.1
Median PSA Level	6.3	0–5300	5.2	0–20	5.3	0.1–20	9.4	
PSA Level								
<2.5	1052	5.7	544	10.4	302	7.2	206	2.3
2.5–4	1892	10.3	791	15.2	612	14.6	489	5.5
4–10	9376	51.1	3161	60.6	2752	65.7	3463	38.7
10–20	2533	13.8	597	11.5	499	11.9	1437	16.1
>20	2403	13.1	0	0	0	0	2403	26.9
Unknown	1087	5.9	120	2.3	23	0.6	944	10.6
Clinical Stage								
T1c	7727	42.1	2694	51.7	2786	66.5	2247	25.1
T2–T3	3542	19.3	769	14.7	986	23.5	1787	20
Unknown	7074	38.6	1750	33.6	416	9.9	4908	54.9
Pathologic Stage								
T1–T2	10266	56	4663	89.4	3569	85.2	2034	22.8
T3–T4	5001	27.3	0	0	0	0	5001	55.9

	Overall		Non-Aggressive		Intermediate Aggressive		Aggressive	
	N	%	N	%	N	%	N	%
Unknown	3076	16.8	550	10.6	619	14.8	1907	21.3
Clinical Gleason Score								
6	1041	37.5	497	100	212	39.3	340	19.6
7	663	24	0	0	328	60.7	327	18.9
8–10	1064	38.5	0	0	0	0	1064	61.5
Pathologic Gleason Score								
I6	7729	50.9	4716	100	1568	43.1	1451	21.2
7	5058	33.3	0	0	2068	56.9	2984	43.7
8–10	2400	15.8	0	0	0	0	2400	35.1
Unknown Gleason	388	2.1	0	0	12	0.2	376	4.2
Death from Prostate Cancer	986	5.4	0	0	0	0	986	11
Median Followup Time (years)	4.7	0–29.9	4	0–20	4	0–22	5	0–29.9

Table 2

Case-Case Study Comparing the Genotypes of Men with Aggressive to Non-Aggressive Disease

The OR (95% CI) was calculated from multinomial logistic regression analyses using a saturated model comparing aggressive and non-aggressive disease. The P value is derived from a cumulative logit model comparing aggressive, intermediate and non-aggressive disease.

SNP	Location	Risk Allele	European Ancestry		African American Ancestry	
			OR (95% CI)	P value	OR (95% CI)	P value
rs721048	2p15	A	1.09 (0.98–1.20)	0.105	0.80 (0.49–1.30)	0.353
rs1465618	2p21	A	1.09 (1.00–1.20)	0.053	0.71 (0.41–1.22)	0.210
rs12621278	2q31.1	G	0.95 (0.79–1.15)	0.656	0.51 (0.09–2.84)	0.436
rs2660753	3p12.1	T	0.92 (0.84–1.00)	0.071	0.83 (0.68–1.01)	0.047
rs10934853	3q21	A	1.03 (0.94–1.13)	0.507	0.79 (0.26–2.35)	0.617
rs12500426	4q22.3	A	1.02 (0.94–1.10)	0.649	1.15 (0.67–1.96)	0.816
rs17021918	4q22.3	T	1.03 (0.94–1.14)	0.555	1.00 (0.57–1.77)	0.997
rs7679673	4q24	A	1.04 (0.96–1.13)	0.378	1.28 (0.84–1.96)	0.238
rs2736098	5p15	A	1.10 (0.88–1.37)	0.249	1.82 (0.62–5.33)	0.285
rs401681	5p16 (TERT)	C	0.89 (0.77–1.02)	0.120	1.12 (0.42–2.99)	0.724
rs9364554	6q25.3 (SLC22A3)	T	1.03 (0.95–1.12)	0.436	0.86 (0.58–1.27)	0.429
rs10486567	7p15.2 (JAZF1)	G	0.94 (0.87–1.01)	0.060	0.92 (0.74–1.15)	0.436
rs6465657	7q21.3 (LMTK2)	C	0.95 (0.90–1.01)	0.155	0.91 (0.50–1.66)	0.733
rs1512268	8p21.2	A	1.03 (0.95–1.11)	0.569	1.07 (0.70–1.62)	0.785
rs16901979	8q24	A	1.15 (1.00–1.32)	0.051	1.12 (0.90–1.40)	0.355
rs16902094	8q24	G	1.02 (0.92–1.14)	0.643	1.22 (0.24–6.31)	0.836
rs445114	8q24	T	0.98 (0.89–1.08)	0.714	1.46 (0.53–4.02)	0.558
rs6983267	8q24	G	1.00 (0.94–1.06)	0.832	1.23 (0.84–1.78)	0.234
rs1447295	8q24	A	1.02 (0.94–1.11)	0.621	0.87 (0.71–1.08)	0.249
rs10086908	8q24	C	1.07 (0.97–1.18)	0.187	0.73 (0.20–2.63)	0.693
rs1571801	9q33.2	A	0.97 (0.90–1.03)	0.304	1.14 (0.86–1.51)	0.380
rs10993994	10q11 (MSMB)	T	0.96 (0.91–1.02)	0.180	0.85 (0.69–1.03)	0.116
rs4962416	10q26.13	C	0.92 (0.84–1.00)	0.052	0.98 (0.76–1.27)	0.805
rs7127900	11p15.5	A	0.92 (0.84–1.01)	0.108	0.78 (0.51–1.20)	0.287

SNP	Location	Risk Allele	European Ancestry		African American Ancestry	
			OR (95% CI)	P value	OR (95% CI)	P value
rs11228565	11q13	A	1.01 (0.91–1.13)	0.774	1.30 (0.16–10.90)	0.733
rs10896450	11q13	G	0.95 (0.82–1.09)	0.450	0.62 (0.24–1.58)	0.376
rs12418451	11q13.3	A	1.00 (0.90–1.11)	0.936	0.77 (0.08–7.75)	0.761
rs4054823	17p12	T	1.09 (1.00–1.19)	0.088	--	
rs11649743	17q12	G	0.99 (0.91–1.07)	0.755	0.96 (0.62–1.49)	0.898
rs4430796	17q12	A	1.00 (0.95–1.06)	0.948	1.05 (0.86–1.29)	0.610
rs1859962	17q24	G	0.99 (0.94–1.05)	0.803	1.06 (0.86–1.31)	0.493
rs8102476	19q13	C	1.07 (0.98–1.16)	0.097	0.93 (0.33–2.62)	0.958
rs2735839	19q13.3 (KLK2/KLK3)	G	0.77 (0.69–0.87)	1.042×10^{-5}	0.72 (0.58–0.89)	2.0×10^{-4}
rs9623117	22q13.1	C	1.00 (0.93–1.09)	0.994	1.00 (0.17–6.01)	0.648
rs5759167	22q13.2	T	0.96 (0.88–1.04)	0.294	1.35 (0.70–2.59)	0.536
rs5945572	Xp11	A	0.93 (0.83–1.04)	0.270	0.94 (0.68–1.30)	0.687

Table 3

Analysis of Genotype Association with Gleason Score

The OR (95% CI) was calculated from multinomial logistic regression analyses using a saturated model comparing high-grade and low-grade disease. The P value is derived from a cumulative logit model comparing high-, intermediate- and low-grade disease.

			European Ancestry		African American Ancestry	
SNP	**Location**	**Risk Allele**	**OR (95% CI)**	**P value**	**OR (95% CI)**	**P value**
rs721048	2p15	A	1.08 (0.77–1.11)	0.259	0.76 (0.41–1.41)	0.686
rs1465618	2p21	A	1.08 (0.98–1.20)	0.047	1.22 (0.72–2.07)	0.919
rs12621278	2q31.1	G	0.93 (0.73–1.17)	0.538	--	
rs2660753	3p12.1	T	0.99 (0.88–1.10)	0.510	0.95 (0.76–1.18)	0.137
rs10934853	3q21	A	0.95 (0.86–1.05)	0.454	1.94 (0.65–5.84)	0.447
rs12500426	4q22.3	A	1.01 (0.93–1.11)	0.992	1.04 (0.64–1.67)	0.395
rs17021918	4q22.3	T	1.06 (0.95–1.18)	0.122	0.91 (0.55–1.48)	0.514
rs7679673	4q24	A	1.03 (0.94–1.13)	0.310	1.17 (0.79–1.72)	0.407
rs2736098	5p15	A	1.10 (0.80–1.50)	0.578	0.87 (0.25–3.04)	0.811
rs401681	5p16 (TERT)	C	0.94 (0.82–1.07)	0.293	1.77 (0.65–4.77)	0.194
rs9364554	6q25.3 (SLC22A3)	T	0.90 (0.82–0.98)	0.114	0.96 (0.61–1.51)	0.904
rs10486567	7p15.2 (JAZF1)	G	0.89 (0.82–0.97)	0.003	0.86 (0.68–1.10)	0.091
rs6465657	7q21.3 (LMTK2)	C	0.92 (0.86–1.00)	0.014	0.80 (0.47–1.38)	0.444
rs1512268	8p21.2	A	0.97 (0.89–1.06)	0.785	0.86 (0.58–1.28)	0.776
rs16901979	8q24	A	1.18 (1.00–1.39)	0.072	1.07 (0.83–1.36)	0.836
rs16902094	8q24	G	1.02 (0.89–1.16)	0.709	0.89 (0.18–4.36)	0.695
rs445114	8q24	T	0.96 (0.86–1.07)	0.330	1.28 (0.46–3.55)	0.764
rs6983267	8q24	G	0.94 (0.88–1.00)	0.076	1.16 (0.76–1.79)	0.209
rs1447295	8q24	A	1.04 (0.93–1.15)	0.104	1.05 (0.82–1.33)	0.548
rs10086908	8q24	C	1.06 (0.94–1.18)	0.439	0.94 (0.34–2.61)	0.960
rs1571801	9q33.2	A	0.98 (0.91–1.07)	0.951	1.41 (1.04–1.91)	0.198
rs10993994	10q11 (MSMB)	T	0.94 (0.88–1.01)	0.127	0.89 (0.71–1.11)	0.289
rs4962416	10q26.13	C	0.95 (0.86–1.04)	0.348	1.04 (0.77–1.40)	0.863
rs7127900	11p15.5	A	0.82 (0.73–0.92)	0.002	1.12 (0.75–1.67)	0.816

SNP	Location	Risk Allele	European Ancestry		African American Ancestry	
			OR (95% CI)	P value	OR (95% CI)	P value
rs11228565	11q13	A	1.05 (0.92–1.19)	0.765	4.49 (0.78–26.00)	0.054
rs10896450	11q13	G	0.98 (0.84–1.16)	0.829	0.76 (0.28–2.09)	0.708
rs12418451	11q13.3	A	0.98 (0.85–1.13)	0.869	0.83 (0.22–3.16)	0.868
rs4054823	17p12	T	1.03 (0.94–1.14)	0.352	4.72 (1.24–17.89)	0.025
rs11649743	17q12	G	0.95 (0.86–1.05)	0.096	1.05 (0.63–1.75)	0.684
rs4430796	17q12	A	1.05 (0.98–1.13)	0.513	0.94 (0.74–1.19)	0.956
rs1859962	17q24	G	0.95 (0.88–1.02)	0.093	0.97 (0.77–1.22)	0.297
rs8102476	19q13	C	1.00 (0.91–1.10)	0.717	1.53 (0.53–4.41)	0.477
rs2735839	19q13.3 (KLK2/KLK3)	G	0.77 (0.68–0.86)	1.862×10^{-5}	0.69 (0.54–0.87)	4.667×10^{-4}
rs9623117	22q13.1	C	0.96 (0.87–1.07)	0.746	1.74 (0.72–4.19)	0.117
rs5759167	22q13.2	T	0.98 (0.89–1.07)	0.599	0.99 (0.54–1.80)	0.267
rs5945572	Xp11	A	0.87 (0.77–0.99)	0.128	1.17 (0.82–1.68)	0.655

Table 4

Subgroup analysis based upon PSA level comparing the association between SNP rs2735839 and high-risk disease

Of note, there were not enough African-African men with very low PSA values to make meaningful comparisons.

	SNP	Location	Risk Allele	European Ancestry		African American Ancestry	
				OR (95% CI)	P value	OR (95% CI)	P value
PSA 20.0 ng/ml	rs2735839	19q13.3 (KLK2/KLK3)	G	0.73 (0.64–0.83)	1.622×10^{-5}	0.76 (0.59–0.98)	0.019
PSA 10.0 ng/ml	rs2735839	19q13.3 (KLK2/KLK3)	G	0.68 (0.59–0.79)	1.302×10^{-5}	0.82 (0.61–1.10)	0.067
PSA 4.0 ng/ml	rs2735839	19q13.3 (KLK2/KLK3)	G	0.70 (0.52–0.94)	0.0092	N/A	N/A